Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma
Ryul Kim(Seoul Metropolitan Government), Dae Seog Heo(Seoul National University)
Cited by 31
Related Papers
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2011|320
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
|Oncotarget|2017|87
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
|Cancer Research and Treatment|2018|66
Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients
|Scientific Reports|2019|46
Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
|Cancer Research and Treatment|2018|28